急性髓系白血病 (AML) 是成人中最常见的白血病，是一种由克隆增殖的造血干细胞引起的生物异质性疾病。对新型遗传方法的日益重视提高了对 AML 生物学的理解。最近，新兴的代谢组学领域表明了 AML 发病机制、进展和治疗中代谢谱的定性和定量变化。多种代谢和分子途径调节人体新陈代谢，宿主-微生物组相互作用可能会显着影响这种生化机制。研究发现微生物群在造血功能、代谢和免疫方面发挥着重要作用，有助于 AML 的发生。大量研究强调了肠道微生物群 (GM) 的组成和多样性对 AML 治疗和预后的重要性。此外，强有力的证据强调了菌群失调与感染性并发症之间的有​​害联系，感染性并发症是 AML 患者发病和死亡的主要原因。迄今为止，几种微生物相关的机制已与宿主生理学的特定变化相关，而微生物衍生的代谢物属于最重要的机制之一。它们在体内循环，调节局部和全身的人体状况。细菌代谢功能的广泛而多样的功能在包括白血病发生在内的许多过程中发挥着关键作用。微生物组和代谢组数据的综合分析是一个有前途的途径，可以更好地了解微生物群、生化改变和 AML 发病机制之间的复杂关系，从而有效预防、治疗和减轻其后果。本综述重点关注微生物衍生代谢物在 AML 中的病理作用和治疗意义。

Acute myeloid leukemia (AML), the most common leukemia in adults, is a biologically heterogeneous disease arising from clonally proliferating hematopoietic stem cells. Increased appreciation of novel genetic methods has improved the understanding of AML biology. Recently, the emerging field of metabolomics has indicated qualitative and quantitative alterations in metabolic profiles in AML pathogenesis, progression and treatment. Multiple metabolic and molecular pathways regulate human metabolism and host-microbiome interactions may significantly affect this biochemical machinery. Microbiota have been found to play a significant role in hematopoietic function, metabolism and immunity, contributing to AML occurrence. A large number of studies have highlighted the importance of the composition and diversity of the gut microbiota (GM) in response to treatment and prognosis in AML. Moreover, strong evidence emphasizes the detrimental link between dysbiosis and infectious complications, a leading cause of morbidity and mortality for patients with AML. Several microbiota-related mechanisms have been linked to particular changes in host physiology so far, and microbial-derived metabolites belong to one of the most important. Circulating in the body, they modulate human conditions both locally and systemically. The extensive and diverse repertoire of bacterial metabolic functions plays a critical role in numerous processes, including leukemogenesis. Integrative analysis of microbiome and metabolome data is a promising avenue for better understanding the complex relationship between the microbiota, biochemical alterations and AML pathogenesis to effectively prevent, treat and mitigate its outcomes. This review concentrates on the pathologic roles and therapeutic implications of microbe-derived metabolites in AML settings.